# OnCo record xu-binghe (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/xu-binghe/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "xu-binghe" ;
  schema:name "Binghe Xu"@en ;
  schema:description "Principal investigator of OptiTROP-Breast01, the Chinese trial that got the TROP2 ADC sacituzumab tirumotecan approved before any Western approval."@en ;
  schema:url <https://onco.cc/people/xu-binghe/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.cicams.ac.cn>, <https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20B%5BAuthor%5D%20Chinese%20Academy%20of%20Medical%20Sciences%20breast%20cancer> ;
  schema:jobTitle "Professor of Medical Oncology; Director, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/pyrotinib/> ;
  onco:companies <https://onco.cc/companies/kelun-biotech/>, <https://onco.cc/companies/hengrui/> ;
  onco:institutions <https://onco.cc/institutions/cams-cancer-hospital/> ;
  schema:affiliation <https://onco.cc/institutions/cams-cancer-hospital/> .